Preferred Label : Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells;
NCIt definition : An autologous tumor cell vaccine containing CD34 hematopoietic progenitor cell (HPC)-derived
Langerhans-type dendritic cells (LCs) electroporated with mRNA encoding the full-length
cancer-testis antigens, CT7 and melanoma-associated antigen 3 (MAGE-A3), and the self-differentiation
tumor antigen, Wilms tumor 1 (WT1) with potential immunomodulating and antineoplastic
activity. The autologous CT7/MAGE-A3/WT1 mRNA-electroporated Langerhans-type dendritic
cells are prepared by drawing a blood sample containing the CD34 HPCs from a cancer
patient. The CD34 HPCs are treated with a combination of cytokines which specifically
support LC development, and the LC population is enriched and expanded ex vivo. The
cultured LCs are allowed to mature for one day and then electroporated separately
with CT7, MAGE-A3 or WT1 mRNA before final maturation. Upon intradermal administration
into the patient, the mature LCs may activate cell-mediated immunity and induce both
cytotoxic CD8 T cells and CD4 helper T cells against cancer cells expressing CT7,
MAGE-A3 and WT1 tumor antigens. This may result in the immune-mediated inhibition
of tumor cell proliferation, leading to tumor cell death. CT7 and MAGE-A3 are tumor-specific
proteins overexpressed in a number of cancers but not in healthy tissues other than
testis and placenta. WT1 is a transcription factor important in development and cancer
pathogenesis, which is overexpressed in a variety of cancers, including multiple myeloma,
leukemia, ovarian cancer, malignant mesothelioma, neural tumors and renal carcinoma.;
Molecule name : CT7/MAGE-A3/WT1 mRNA-Electroporated LCs;
NCI Metathesaurus CUI : CL455245;
Origin ID : C113174;
UMLS CUI : C3827138;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
